Enliven Therapeutics (ELVN) Gains from Sales and Divestitures (2023 - 2026)
Enliven Therapeutics' (ELVN) quarterly Gains from Sales and Divestitures came in at $14357.0 in Q1 2026, up 38.63% year-on-year from $10356.0 in Q1 2025, and down 52.42% quarter-over-quarter from $30172.0 in Q4 2025.
Enliven Therapeutics (ELVN) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends
Enliven Therapeutics has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $14357.0 for Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $14357.0, up 38.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $14357.0 (up 38.63% YoY), and the FY2025 annual result was $30172.0, up 34.94% from the prior year.
- Gains from Sales and Divestitures came in at $14357.0 for Q1 2026 at Enliven Therapeutics, down from $30172.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $30172.0 in Q4 2025 to a low of $2688.0 in Q1 2024.
- The 4-year median for Gains from Sales and Divestitures is $11867.0 (2023), against an average of $13816.8.
- Across the five-year window, Gains from Sales and Divestitures sank 81.3% in 2024 and surged 285.27% in 2025, its largest moves.
- Enliven Therapeutics' Gains from Sales and Divestitures stood at $7187.0 in 2023, then soared by 211.12% to $22360.0 in 2024, then jumped by 34.94% to $30172.0 in 2025, then plunged by 52.42% to $14357.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $14357.0 (Q1 2026), $30172.0 (Q4 2025), and $23568.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,357.00 |
| Mar 31, 2026 | 14,357.00 |
| Dec 31, 2025 | 30,172.00 |
| Dec 31, 2025 | 30,172.00 |
| Sep 30, 2025 | 23,568.00 |
| Sep 30, 2025 | 23,568.00 |
| Jun 30, 2025 | 16,960.00 |
| Jun 30, 2025 | 16,960.00 |
| Mar 31, 2025 | 10,356.00 |
| Mar 31, 2025 | 10,356.00 |
| Dec 31, 2024 | 22,360.00 |
| Dec 31, 2024 | 22,360.00 |
| Sep 30, 2024 | 6,188.00 |
| Sep 30, 2024 | 6,188.00 |
| Jun 30, 2024 | 4,437.00 |
| Jun 30, 2024 | 4,437.00 |
| Mar 31, 2024 | 2,688.00 |
| Mar 31, 2024 | 2,688.00 |
| Dec 31, 2023 | 7,187.00 |
| Dec 31, 2023 | 7,187.00 |